You are here


The SAFE-N-MEDTECH project seeks to develop an open access platform to provide the necessary knowledge, networks and services for the development of nanotechnology-based medical and diagnostic devices. Access to this platform will provide a careful assessment of the potential risks and benefits of the projects.

The SAFE-N-MEDTECH (acronym for “Safety Testing In The Life Cycle Of Nanotechnology-Enabled Medical Technologies For Health”) platform is an Open Innovation Test Bed (OITB), made up of 27 partners, which provides a comprehensive vision for evaluating nano-enabled medical technologies in terms of risk/benefit. The platform will offer companies and reference laboratories the capabilities, know-how, networks and services needed to develop, test, evaluate, scale up and commercially exploit medical and diagnostic devices based on nanotechnologies.

The project, funded under the H2020 program, will open calls for companies and laboratories to use its services free of charge through its website.

Biocat's role in the European SAFE-N-MEDTECH project

Biocat takes part in the SAFE-N-MEDTECH project with the Council of European BioRegions (CEBR), and along with three other clusters (the Turku Science Park in Finland, the Hellenic BioCluster in Greece, and the Bioindustry Park Silvano Fumero in Italy).

Biocat and the other clusters have four main tasks in the SAFE-N-MEDTECH project, which are primarily aimed at making the OITB sustainable over time:

  • To overhaul the services to be proposed by the OITB, as well as the whole of its business plan, in order to adjust them more closely to the real needs of potential future customers.
  • To revise the new project website, which will centralize these services once the project is completed, as well as the pilot calls for proposals in which companies and laboratories from all over Europe can participate.
  • To support in disseminating and communicating events, calls for proposals and future developments.
  • To define the potential role of clusters in the deployment of the future OITB, in particular aimed at maximizing the use of this infrastructure by companies.

For more information on this project and other possibilities to receive support for your company, please contact Albert Guerrero, Scientific Policy and Internationalization Department at Biocat (